The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 7 November 2005. doi:10.1084/jem.20051150
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 202, Number 9, 1261-1269
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 3205K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asagiri, M.
Right arrow Articles by Takayanagi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asagiri, M.
Right arrow Articles by Takayanagi, H.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Autoamplification of NFATc1 expression determines its essential role in bone homeostasis

Masataka Asagiri1,4,5, Kojiro Sato1,4,5, Takako Usami7, Sae Ochi1,2,4, Hiroshi Nishina8, Hiroki Yoshida6,9, Ikuo Morita3,4, Erwin F. Wagner10, Tak W. Mak11,12, Edgar Serfling13, and Hiroshi Takayanagi1,4,5

1 Department of Cell Signaling, Graduate School
2 Department of Medicine and Rheumatology, Graduate School
3 Department of Cellular Physiological Chemistry, Graduate School
4 Center of Excellence Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
5 Solution Oriented Research for Science and Technology, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan
6 Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan
7 Laboratory of Recombinant Animals, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 101-0062, Japan
8 Department of Developmental and Regenerative Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 101-0062, Japan
9 Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga City, Saga 849-8501, Japan
10 Research Institute of Molecular Pathology, A-1030 Vienna, Austria
11 Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada
12 Department of Medical Biophysics, Advanced Medical Discovery Institute, University of Toronto, Toronto, Ontario M5G 2C1, Canada
13 Department of Molecular Pathology, Institute of Pathology, University of Wüerzburg, D-97080 Wüerzburg, Germany

CORRESPONDENCE Hiroshi Takayanagi: taka.csi{at}tmd.ac.jp

NFATc1 and NFATc2 are functionally redundant in the immune system, but it was suggested that NFATc1 is required exclusively for differentiation of osteoclasts in the skeletal system. Here we provide genetic evidence that NFATc1 is essential for osteoclast differentiation in vivo by adoptive transfer of NFATc1/ hematopoietic stem cells to osteoclast-deficient Fos/ mice, and by Fos/ blastocyst complementation, thus avoiding the embryonic lethality of NFATc1/ mice. However, in vitro osteoclastogenesis in NFATc1-deficient cells was rescued by ectopic expression of NFATc2. The discrepancy between the in vivo essential role of NFATc1 and the in vitro effect of NFATc2 was attributed to selective autoregulation of the NFATc1 gene by NFAT through its promoter region. This suggested that an epigenetic mechanism contributes to the essential function of NFATc1 in cell lineage commitment. Thus, this study establishes that NFATc1 represents a potential therapeutic target for bone disease and reveals a mechanism that underlies the essential role of NFATc1 in bone homeostasis.


Abbreviations used: AP, activator protein; BMM, bone marrow monocyte/macrophage precursor cell; CBP, CREB-binding protein; ChIP, chromatin immunoprecipitation; ES, embryonic stem; FLC, fetal liver cell; MeCP2, methyl-CpG binding protein 2; RANKL, receptor activator of NF-{kappa}B ligand.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

NFATc1 self-promotes to build bone
Heather L. Van Epps
J. Exp. Med. 2005 202: 1156. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS